← Browse by Condition
Medical Condition

radiotherapy

Total Trials
10
Recruiting Now
10
Trial Phases
Phase 2
NCT06249321 Phase 2
Recruiting

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Enrollment
30 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT04684186
Recruiting

Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer

Enrollment
60 pts
Location
Switzerland
Sponsor
Centre Hospitalier Universitai...
View Trial →
NCT06389422 Phase 2
Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Enrollment
30 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT06688760
Recruiting

Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

Enrollment
86 pts
Location
China
Sponsor
Ming-Yuan Chen
View Trial →
NCT05554276 Phase 2
Recruiting

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Enrollment
36 pts
Location
China
Sponsor
Shanghai Jiao Tong University ...
View Trial →
NCT07071103 Phase 2
Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Enrollment
48 pts
Location
China
Sponsor
Chuangzhen Chen
View Trial →
NCT06256705
Recruiting

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Enrollment
80 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT07230639 Phase 2
Recruiting

Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial

Enrollment
52 pts
Location
China
Sponsor
Sixth Affiliated Hospital, Sun...
View Trial →
NCT06356584 Phase 2
Recruiting

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Enrollment
62 pts
Location
China
Sponsor
Shandong Cancer Hospital and I...
View Trial →
NCT06433817
Recruiting

Spectral CT in Radiotherapy for Cervical Cancer

Enrollment
150 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →